Login to Your Account

Biotie stock dips as UCB drops tozadenant in Parkinson’s disease

By Cormac Sheridan
Staff Writer

Friday, March 21, 2014
Shares in Biotie Therapies Oyj dipped 7 percent Friday as partner UCB SA opted not to pursue phase III development of the Parkinson’s disease drug tozadenant, a selective inhibitor of the adenosine 2a (A2A) receptor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription